Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

Launched by NEW YORK MEDICAL COLLEGE · Aug 29, 2017

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for children, adolescents, and young adults who have a serious adenovirus infection that hasn’t responded to standard antiviral therapies, particularly after undergoing stem cell transplants. The researchers will be giving participants specially made immune cells, called adenovirus-specific cytotoxic T-lymphocytes, which are designed to help the body fight off the adenovirus. This is especially important for patients who have primary immune deficiencies or have received solid organ transplants, as they are more vulnerable to infections.

To be eligible for this trial, patients must have a persistent adenovirus infection that hasn't improved with two weeks of appropriate antiviral treatment or have severe symptoms like lung or bladder inflammation. They should also have a related donor who can provide the special immune cells needed for the treatment. Participants will need to provide written consent, and they can expect close monitoring throughout the trial. Importantly, this trial is currently recruiting participants of all ages, from infants to adults, and aims to offer hope for those struggling with difficult-to-treat adenovirus infections.

Gender

ALL

Eligibility criteria

• 1. Patients with Adenovirus infections post allogeneic HSCT, with primary immunodeficiencies or post solid organ transplant with:
• • Increasing or persistent quantitative ADV RT-PCR DNA copies despite two weeks of appropriate anti-viral therapy and/or
• • clinical symptoms attributed to adenovirus, including pneumonitis, hemorrhagic cystitis, colitis, hepatitis AND/OR
• * Medical intolerance to anti-viral therapies including:
• • grade 2 renal insufficiency secondary to cidofovir Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.
• • Performance Status \> 30% (Lansky \< 16 yrs and Karnofsky \> 16 yrs) Age: 0.1 to 79 years
• • Females of childbearing potential with a negative urine pregnancy test
• • 2. Donor Eligibility Related donor available with a T-cell response to the viral MACS® GMP PepTivator antigen(s) of adenovirus.
• • a. Third Party Related Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party allogeneic donor (family donor \> 1 HLA A, B, DR match to recipient) with a T-cell response at least to the viral MACS® GMP PepTivator antigen(s) of adenovirus.
• • AND Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).
• • AND Obtained informed consents by donor or donor legally authorized representative prior to donor collection.
• 3. Patient exclusion criteria:
• A patient meeting any of the following criteria is not eligible for the present study:
• • . Patient with acute GVHD \> grade 2 or extensive chronic GVHD at the time of CTL infusion Patient receiving steroids (\>0.5 mg/kg prednisone equivalent) at the time of CTL infusion Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL infusion Patient with poor performance status determined by Karnofsky (patients \>16 years) or Lansky (patients ≤16 years) score ≤30% Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory adenovirus infection(s) Any medical condition which could compromise participation in the study according to the investigator's assessment Known HIV infection Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.
• • Known hypersensitivity to iron dextran Patients unwilling or unable to comply with the protocol or unable to give informed consent.
• • Known human anti-mouse antibodies
• • -